Summit Therapeutics Inc.'s SEC filings document the company's oncology development business, regulatory updates, governance, and capital structure. Form 8-K reports cover financial results, Regulation FD presentations, ivonescimab clinical data, FDA acceptance of the Biologics License Application, and clinical collaboration disclosures involving investigational cancer combinations.
Definitive proxy materials describe board matters, executive compensation, equity awards, shareholder voting items, and governance practices. The filing record also includes material-event disclosures, material agreements, operating and financial results, and capital-structure information for Summit's Nasdaq-listed common stock and its development rights to ivonescimab.
Summit Therapeutics Inc. filed a prospectus supplement to its automatic shelf registration statement on Form S-3 and included Baker & Hostetler LLP’s opinion on the legality of issuing the common shares set forth in that supplement.
Summit Therapeutics Inc. (SMMT) registered up to 108,955,369 shares of common stock for resale by AstraZeneca Holdings B.V., issuable upon conversion of preferred stock. Summit is not selling shares in this supplement and will receive no proceeds from the resale.
The shares stem from a private placement that closed October 5, 2026: Summit issued 108,955.3686 Class A Convertible Preferred Stock shares for $2.0 billion in aggregate gross proceeds, at $18,356.14 per preferred share. Each preferred share converts into 1,000 common shares; the purchase price was based on $18.3561 per common share. AstraZeneca may sell some, all or none at prevailing market prices, prices related to prevailing market prices or privately negotiated prices, subject to the Purchase Agreement.
Summit’s Q1 2026 report concluded there was substantial doubt about its ability to continue as a going concern because March 31, 2026 cash, cash equivalents and short-term investments were insufficient to fund planned operations for the twelve months after that report’s issuance. Summit bears registration costs other than the selling stockholder’s underwriting fees, commissions, discounts and transfer taxes.
Summit Therapeutics Inc. (SMMT) reported a third-quarter net loss of $208.4 million, versus $231.8 million a year earlier; nine-month net loss was $613.5 million versus $860.4 million. Nine-month research and development expense rose to $459.5 million from $390.4 million, and operating cash use increased to $423.2 million from $221.0 million.
At September 30, 2026, Summit had $150.8 million of cash and equivalents and $479.0 million of short-term investments. AstraZeneca's equity investment closed October 5, delivering $2.0 billion in gross proceeds. Summit issued preferred shares convertible into 108,955,369 common shares; conversion is subject to the HSR waiting period and shareholder approval, which was obtained November 4. The preferred and conversion shares carry a one-year lock-up after closing.
Summit is advancing ivonescimab in multiple oncology trials. For its BLA in EGFR-mutated NSCLC, the FDA set a November 14, 2026 goal action date and said a statistically significant overall-survival benefit is necessary; progression-free-survival results may not suffice. The June 2026 HARMONi analysis reported an overall-survival hazard ratio of 0.76 in the global population.
Summit Therapeutics Inc. reported a third-quarter 2026 GAAP net loss of $208.4 million, compared with $231.8 million a year earlier; non-GAAP net loss was $160.7 million versus $101.0 million. Cash, cash equivalents and short-term investments totaled $629.8 million at September 30, 2026, and the company used $423.2 million in operating cash during the first nine months.
AstraZeneca completed a $2.0 billion strategic equity investment on October 5, purchasing approximately 108,955 preferred shares convertible into common stock at a 1:1,000 ratio. Stockholders approved an amendment increasing authorized common shares from 1,000,000,000 to 2,000,000,000; it became effective upon filing November 4.
In global Phase III HARMONi, progression-free survival met its primary endpoint, but the primary overall-survival analysis showed a positive trend without statistical significance. The FDA said a statistically significant overall-survival benefit is necessary to support marketing authorization; its PDUFA goal date is November 14, 2026. Separately, Akeso-sponsored Phase III studies reported statistically significant overall-survival results: HARMONi-2 versus pembrolizumab (hazard ratio 0.73) and HARMONi-GI1 versus durvalumab plus chemotherapy (0.75).
Summit Therapeutics Inc. is asking stockholders to approve a charter amendment that would increase authorized common shares by 1,000,000,000, from 1,000,000,000 to 2,000,000,000. The board unanimously recommends a FOR vote at the virtual special meeting on November 4, 2026; approval requires a majority of votes cast.
As of October 1, 2026, Summit had 799,726,418 common shares outstanding and 66,727,073 authorized, unreserved shares available, excluding additional shares issuable under the ATM program or private placement. The amendment is intended in part to permit conversion of Class A Preferred Stock issued in a private placement that closed October 5, 2026, for $2.0 billion in gross proceeds to Summit; 108,955,369 common shares are issuable on conversion after any applicable Hart-Scott-Rodino waiting period or extension expires or terminates and the amendment becomes effective.
Summit agreed to take all actions necessary to amend its charter by December 31, 2026. If the required increase is not effective by April 5, 2028, Summit must redeem all outstanding Class A Preferred Stock for cash at a price reflecting the then-prevailing market value of the underlying common stock. The amendment itself would not immediately dilute holders, though future issuance could reduce their voting power and percentage interests.
On October 8, 2026, Summit Therapeutics Inc. Chief Accounting Officer Bhaskar Anand received a grant of 100,000 restricted stock units under the company's Amended and Restated 2020 Stock Incentive Plan. The units vest on October 8, 2029, subject to his continued employment, and each vested unit entitles him to one common share. His direct holdings after the grant were 261,047 shares, including shares previously acquired through the employee stock purchase plan.
Summit Therapeutics Inc. (SMMT) asks stockholders to approve an increase of 1,000,000,000 authorized common shares, from 1,000,000,000 to 2,000,000,000. Approval requires a majority of votes cast, and the board unanimously recommends “FOR.” The amendment would take effect upon filing with Delaware’s Secretary of State, with filing timing determined by the board.
The request supports a preferred-stock private placement that closed October 5, 2026, for $2.0 billion in gross proceeds. The 108,955.3686 Class A preferred shares issued are convertible into 108,955,369 common shares, subject to any applicable Hart-Scott-Rodino waiting period and the amendment’s effectiveness. Summit agreed to file the required amendment by December 31, 2026. As of October 1, 2026, 799,726,418 common shares were outstanding and 66,727,073 authorized, unreserved shares were available, excluding additional shares issuable under the ATM program and private placement. The increase itself would not immediately dilute holders, though future share issuances could. If the amendment is not effective by April 5, 2028, the preferred shares become redeemable for cash at a price reflecting the then-prevailing market value of the underlying common stock.
Summit Therapeutics Inc. agreed to sell AstraZeneca Holdings B.V. 108,955.3686 shares of newly designated Class A Convertible Preferred Stock for $2.0 billion in gross proceeds; closing is expected within five business days, subject to customary closing conditions. The stated common-stock equivalent price is $18.3561 per share. Each preferred share is convertible into 1,000 common shares, but holder-option conversion cannot occur until the later of any applicable HSR waiting-period expiration or termination, including any extension, and effectiveness of an authorized-share increase charter amendment.
A Summit subsidiary also entered a clinical-trial collaboration with AstraZeneca to evaluate ivonescimab with sonesitatug vedotin; the parties will contribute compounds and share study costs, with AstraZeneca intended to sponsor studies, and each retains development and commercial rights to its own molecule. A separate non-binding memorandum records intent to pursue trials with other AstraZeneca cancer medicines. Summit will file a resale registration statement as soon as reasonably practicable and no later than 60 days after closing. If the charter amendment is not effective within 18 months after initial issuance, Summit must redeem all outstanding preferred shares for cash at a price reflecting the then-prevailing market value of the underlying common stock.
Summit Therapeutics Inc. (SMMT) reported updated overall survival data for ivonescimab from the global Phase III HARMONi trial in EGFR‑mutated non-small cell lung cancer, showing a hazard ratio of 0.76 (95% CI: 0.61–0.95; nominal p=0.0151) for overall survival in the global intention‑to‑treat population versus placebo plus chemotherapy at the June 2026 data cut. Median overall survival remained 16.8 months for ivonescimab plus chemotherapy and 14.0 months for placebo plus chemotherapy across data cuts, while western patients showed convergence of benefit with a hazard ratio of 0.76 (95% CI: 0.52–1.10) and median overall survival of 17.5 vs 14.0 months at the latest analysis. Safety in HARMONi continued to be described as acceptable and manageable with no new signals. Summit highlighted that its Biologics License Application for ivonescimab in this setting has an FDA PDUFA goal action date of November 14, 2026.
Separately, Akeso’s China-based Phase III HARMONi-2 trial in NSCLC showed ivonescimab monotherapy improved median overall survival to 30.8 months versus 22.6 months with pembrolizumab (hazard ratio 0.73, 95% CI: 0.57–0.95; p=0.009), with consistent benefits in key PD‑L1 and histology subgroups and a safety profile characterized as acceptable and manageable.
Summit Therapeutics Inc. (SMMT) reported that partner Akeso Inc. presented updated overall survival data from the randomized, double-blind Phase III HARMONi-2 trial of ivonescimab versus pembrolizumab in PD-L1–positive advanced non-small cell lung cancer in China.
In the intention-to-treat population of 398 patients and a median follow-up of 36.0 months, ivonescimab monotherapy achieved a median overall survival of 30.8 months versus 22.6 months for pembrolizumab, with an overall survival hazard ratio of 0.73 (95% CI: 0.57–0.95; p=0.009). A notable benefit was seen in the PD-L1 high subgroup (score ≥50%; n=168) with a hazard ratio of 0.58 (95% CI: 0.38–0.89), and positive trends were reported across PD-L1 low and histology subgroups.
Ivonescimab showed an acceptable and manageable safety profile, with serious treatment-related adverse events in 29.9% of ivonescimab patients versus 21.6% on pembrolizumab, and low discontinuation rates in both arms. Akeso received Chinese marketing authorization for ivonescimab in 2025 based on HARMONi-2, while Summit is running multiple global Phase III studies, including the HARMONi-7 trial targeting about 780 patients and a separate HARMONi study that has led to a Biologics License Application accepted by the FDA with a goal PDUFA date of November 14, 2026.